The CBA-100 product was registered in the Cuban Industrial Property Office, as a supplement and medicine for human and animal use and one hundred percent organic, which was conceived by two people from Holguín during the confrontation with the COVID-19 pandemic in the province.
The Center for State Control of Medicines, Equipment and Medical Devices (Cecmed by its Spanish acronym) granted the Conditional Sanitary Registration to Nasalferon, a nasal application solution for the prophylaxis of SARS-CoV-2 infection, the virus that causes COVID-19.
After the application of the ninth dose of Jusvinza to the third and last group of patients with moderately to severely active rheumatoid arthritis concluded in Holguin the expanded intervention study with this biotechnological product.
Exchanging and updating knowledge in favor of patients care is one of the main objectives of the scientific events taking place this week at the University of Medical Sciences (UCMHo) of the city of Holguín, with the participation of professionals from different medical disciplines.